Microbiome in Atopic Dermatitis Under Systemic Therapy

Condition(s) studied

Investigational drug(s) / intervention(s)

not applicable, observational study: Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study

Study summary

The skin microbiome plays a role in the pathogenesis of atopic dermatitis. However, it is unclear whether the range of microbiota on the skin is the cause or consequence of atopic skin inflammation.

The influence of new systemic therapies for the treatment of moderate to severe atopic dermatitis (such as biologics or Janus kinase inhibitors) on the skin microbiome is largely unknown.

The main aim of this scientific exploratory study is to investigate whether and how the skin microbiome changes in patients with moderate to severe atopic dermatitis during systemic therapy. This not only allows new hypotheses to be generated on the pathogenesis of atopic dermatitis, but also new objective scales for the severity of atopic dermatitis can be developed.

Eligibility

Primary outcome measure(s)

• Comparison of the microbial composition — 1 year
  Comparison of the microbial composition of the skin before, 6 and 12 months after the initiation of systemic therapy.
• Comparison of microbial composition of the skin with serological biomarkers — 1 year
  Comparison of microbial composition of the skin with serological biomarkers (z.B.TARC, TSLP, CCL27).

Trial sites (1)

More Charite University, Berlin, Germany trials in Germany

Other trials for the same condition